We have identified three broad areas for future work in this area: (1) establishing standards for CLS-B assessment; (2) assessing the role of CLS-B in breast cancer incidence, and (3) assessing the role of CLS-B on therapeutic effectiveness and breast cancer prognosis. The gene discussed is PPIB; the disease is breast carcinoma.